Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 205,666 |
|
|||||
| News | - | ||||||
| Day High | 22.90 | Low High |
|||||
| Day Low | 22.75 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Exelixis Inc | EXEL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.105 | 0.46% | 22.805 | 10:43:27 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 22.755 | 22.75 | 22.90 | 22.70 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,398 | 205,666 | $ 22.83 | $ 4,694,357 | - | 18.08 - 24.34 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:44:02 | 1 | $ 22.805 | USD |
Exelixis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.91B | 303.19M | - | 1.83B | 207.77M | 0.69 | 33.26 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Exelixis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EXEL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 23.33 | 23.795 | 22.42 | 23.02 | 1,767,015 | -0.525 | -2.25% |
| 1 Month | 23.19 | 24.07 | 22.42 | 23.48 | 2,041,101 | -0.385 | -1.66% |
| 3 Months | 22.60 | 24.07 | 20.015 | 22.21 | 2,263,468 | 0.205 | 0.91% |
| 6 Months | 21.38 | 24.34 | 18.64 | 22.01 | 2,280,231 | 1.43 | 6.67% |
| 1 Year | 19.50 | 24.34 | 18.08 | 21.08 | 2,333,213 | 3.31 | 16.95% |
| 3 Years | 23.91 | 25.77 | 14.87 | 19.59 | 2,336,963 | -1.11 | -4.62% |
| 5 Years | 23.16 | 27.90 | 13.67 | 20.05 | 2,466,842 | -0.355 | -1.53% |
Exelixis Description
| Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
